NO139640C - Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner - Google Patents

Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner

Info

Publication number
NO139640C
NO139640C NO2059/73A NO205973A NO139640C NO 139640 C NO139640 C NO 139640C NO 2059/73 A NO2059/73 A NO 2059/73A NO 205973 A NO205973 A NO 205973A NO 139640 C NO139640 C NO 139640C
Authority
NO
Norway
Prior art keywords
16alfa
dioxypregna
dioner
17alfa
alkyliden
Prior art date
Application number
NO2059/73A
Other languages
English (en)
Norwegian (no)
Other versions
NO139640B (no
Inventor
Ralph Lennart Brattsand
Karl Goeran Claeson
Bo Thureson Af Ekenstam
Bror Arne Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO139640(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bofors Ab filed Critical Bofors Ab
Publication of NO139640B publication Critical patent/NO139640B/no
Publication of NO139640C publication Critical patent/NO139640C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO2059/73A 1972-05-19 1973-05-18 Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner NO139640C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (da) 1972-05-19 1972-05-19

Publications (2)

Publication Number Publication Date
NO139640B NO139640B (no) 1979-01-08
NO139640C true NO139640C (no) 1979-04-18

Family

ID=20269234

Family Applications (2)

Application Number Title Priority Date Filing Date
NO2059/73A NO139640C (no) 1972-05-19 1973-05-18 Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner
NO1994013C NO1994013I1 (no) 1972-05-19 1994-08-31 Budenosid/ 16¿, 17¿-alkyldendioksypregna-1,4-dien-3,20-dioner

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1994013C NO1994013I1 (no) 1972-05-19 1994-08-31 Budenosid/ 16¿, 17¿-alkyldendioksypregna-1,4-dien-3,20-dioner

Country Status (26)

Country Link
US (2) US3929768A (da)
JP (1) JPS5521760B2 (da)
AT (1) AT328630B (da)
BE (1) BE799727A (da)
CA (1) CA1002938A (da)
CH (1) CH595400A5 (da)
CS (1) CS178129B2 (da)
CY (1) CY1013A (da)
DD (1) DD104295A5 (da)
DE (1) DE2323215C3 (da)
DK (1) DK134783B (da)
ES (1) ES414673A1 (da)
FI (1) FI50631C (da)
FR (1) FR2185405B1 (da)
GB (1) GB1429922A (da)
HK (1) HK49179A (da)
HU (1) HU166680B (da)
IL (1) IL42155A (da)
KE (1) KE2970A (da)
NL (2) NL177493C (da)
NO (2) NO139640C (da)
PL (1) PL87765B1 (da)
SE (1) SE378109B (da)
SU (1) SU470954A3 (da)
YU (1) YU35896B (da)
ZA (1) ZA732955B (da)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24B1 (ro) * 1991-07-09 1994-05-31 Parfumerii Si Cosmetice Vioric Compozitie de substante odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
EP0675897B1 (en) * 1992-12-24 1997-06-18 Rhone-Poulenc Rorer Limited New steroids
PL178307B1 (pl) * 1993-01-08 2000-04-28 Astra Ab Nowe pochodne steroidowe, sposób wytwarzania nowych pochodnych steroidowych i preparat farmaceutyczny do leczenia stanu zapalnego śluzówki jelita
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
AU2003291634A1 (en) * 2002-10-08 2004-05-04 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CA2561315A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
JP2009512677A (ja) * 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼタイプｉｖ阻害剤の組成物
JP2009512733A (ja) * 2005-11-02 2009-03-26 シコール インコーポレイティド シクレソニドの改良された製造法
TWI374147B (en) 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
MX2009001963A (es) * 2006-08-22 2009-03-30 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
BRPI0717058A2 (pt) * 2006-09-22 2013-10-15 Ranbaxy Lab Ltd Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2007340129B2 (en) 2006-12-26 2012-02-02 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
RS58936B1 (sr) 2007-01-10 2019-08-30 Msd Italia Srl Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
DK2124944T3 (da) * 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
WO2009045539A2 (en) 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
JP2011513469A (ja) * 2008-03-13 2011-04-28 ファルマビオス ソシエタ ペル アチオニ プレグナン誘導体の製造法
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
HUE047834T2 (hu) 2009-05-29 2020-05-28 Pearl Therapeutics Inc Nyújtott hatású muszkarin antagonisták és nyújtott hatású béta 2 adrenerg receptor agonisták pulmonáris beadására alkalmas készítmények és ezekkel kapcsolatos eljárások és rendszerek
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
CA3037273C (en) 2009-10-01 2022-05-03 Fredric Jay Cohen Orally administered corticosteroid compositions
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013109214A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
EP2888255B1 (en) 2012-08-24 2018-07-18 Board of Regents, The University of Texas System Heterocyclic modulators of hif activity for treatment of disease
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
LT2925888T (lt) 2012-11-28 2018-01-10 Merck Sharp & Dohme Corp. Vėžio gydymo kompozicijos ir būdai
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
KR102275109B1 (ko) 2013-03-15 2021-07-07 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
PE20160155A1 (es) 2013-05-22 2016-04-01 Pearl Therapeutics Inc Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016120891A1 (en) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
WO2018213077A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
MX2020011546A (es) 2018-05-09 2021-01-29 Regeneron Pharma Anticuerpos anti-msr1 y metodos de uso de los mismos.
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3226153A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
US20240208987A1 (en) 2022-10-25 2024-06-27 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (en) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (da) * 1971-10-08 1973-06-25

Also Published As

Publication number Publication date
FI50631B (da) 1976-02-02
PL87765B1 (da) 1976-07-31
ATA436573A (de) 1975-06-15
GB1429922A (en) 1976-03-31
JPS5521760B2 (da) 1980-06-12
YU129173A (en) 1981-02-28
DE2323215C3 (de) 1978-03-30
NL930025I1 (nl) 1993-06-01
DD104295A5 (da) 1974-03-05
NL7306978A (da) 1973-11-21
DE2323215B2 (de) 1977-08-11
KE2970A (en) 1979-07-20
US3929768A (en) 1975-12-30
HK49179A (en) 1979-07-27
DE2323215A1 (de) 1973-11-29
BE799727A (fr) 1973-09-17
CY1013A (en) 1979-11-23
JPS4941378A (da) 1974-04-18
NL177493B (nl) 1985-05-01
NL177493C (nl) 1985-10-01
SU470954A3 (ru) 1975-05-15
SE378109B (da) 1975-08-18
IL42155A (en) 1977-06-30
CH595400A5 (da) 1978-02-15
ES414673A1 (es) 1976-07-01
HU166680B (da) 1975-05-28
FI50631C (fi) 1976-05-10
AU5525373A (en) 1974-11-07
IL42155A0 (en) 1973-07-30
DK134783B (da) 1977-01-17
US3983233A (en) 1976-09-28
FR2185405A1 (da) 1974-01-04
NO1994013I1 (no) 1994-08-31
NO139640B (no) 1979-01-08
FR2185405B1 (da) 1976-12-31
ZA732955B (en) 1974-04-24
DK134783C (da) 1977-06-06
CS178129B2 (da) 1977-08-31
CA1002938A (en) 1977-01-04
AT328630B (de) 1976-03-25
YU35896B (en) 1981-08-31

Similar Documents

Publication Publication Date Title
NO139640C (no) Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner
SE414771B (sv) Forfarande for framstellning av nya 11,11-alkyliden-steroider
SE7505040L (sv) Forfarande for framstellning av n-fosfonometylglycin.
NO138335C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkanolaminer
SE432767B (sv) Forfarande for framstellning av oxazolo-(5,4-b)-pyridiner
NO141800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
NO143460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
SE390819B (sv) Analogiforfarande for framstellning av piperazinyl-propyl-1,2,4-triazolinderivat
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO140731C (no) Fremgangsmaate for fremstilling av dimetyleter
NO142173C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme, 1,1-diaryl-1-oksadiazolalkylaminderivater
SE382053B (sv) Forfarande for framstellning av bifenylylalkanoylaminopyridiner
DK136534C (da) Analogifremgangsmade til fremstilling af d-homopregna-1,4-dien-3,20-dioner
SE7504842L (sv) Forfarande for framstellning av adeninderivat..
SE383151B (sv) Forfarande for framstellning av 1-hydroxi-2-pyridoner
NO139088C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2beta,16beta-diamino-5alfa-androstaner
NO144928C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive zantinderivater.
NO145383C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte indoler.
SE397827B (sv) Forfarande for framstellning av 1-aminometyl-2,2-difenylcyklopropankarboxamidderivat med terapeutisk verkan
SE400768B (sv) Forfarande for framstellning av 2-fenyl-6-sulfamoyl-7-klor-1,2,3,4-tetrahydro-4-kinazolinon
SE380272B (sv) Forfarande for framstellning av n-fosfonmetylglycin
SE399557B (sv) Forfarande for framstellning av tiantren-, tioxanten- och fenoxatiinderivat
FI56830B (fi) Foerfarande foer framstaellning av asparaginylgrupper innehaollande biologiskt aktiva polypeptider
SE400767B (sv) Forfarande for framstellning av arylpiperazin-derivat av adenin
NO140010C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 6-substituerte 3-karbetoksyhydrazinopyridaziner